Fabtech Technologies Limited — Investor Presentation 2025

Nov 6, 2025

==> picture [597 x 93] intentionally omitted <==

Date: November 06, 2025

To,

National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Listing Department Bandra Kurla Complex, Floor 25, P J Towers, Bandra (East), Mumbai – 400051 Dalal Street, Mumbai – 400001 Maharashtra, India. Maharashtra, India. Symbol: FABTECH Scrip Code: 544558

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation in relation to the financial results for the quarter ended June 30, 2025 and for the quarter and half-year ended September 30, 2025.

Request you to take the same on record.

Thank you.

Yours faithfully, For Fabtech Technologies Limited

HEMANT Digitally signed by HEMANT MOHAN MOHAN ANAVKAR Date: 2025.11.06 ANAVKAR 18:26:32 +05'30' ____

Hemant Mohan Anavkar Executive Director DIN: 00150776

Encl.: As mentioned above

==> picture [597 x 78] intentionally omitted <==

==> picture [240 x 321] intentionally omitted <==

==> picture [241 x 321] intentionally omitted <==

==> picture [241 x 321] intentionally omitted <==

==> picture [240 x 321] intentionally omitted <==

==> picture [174 x 86] intentionally omitted <==

Fabtech Technolo ies Limited g

Investor Presentation

Disclaimer

==> picture [82 x 41] intentionally omitted <==

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Fabtech Technologies Limited, (The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantee of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.

These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks.

The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

2

Investor Presentation

Why Turnkey + In-House Manufacturing Matters

o In pharmaceutical, biopharma, and healthcare projects, choosing a turnkey partner with in-house Process, Air & Water manufacturing capabilities is no longer a preference, it's a strategic necessity.

o Single Accountability, Zero Coordination Risk: One partner owns design, engineering, manufacturing, installation, and validation eliminating delays and vendor conflicts.

o Precision-Controlled Environments In-House: Process Equipment & Containment Systems (Process), Cleanrooms (Air) & Purified Water & Distribution (Water) are engineered under one ecosystem ensuring seamless integration and regulatory compliance.

o Speed to Market: In-house manufacturing drastically reduces dependency on imports and fragmented suppliers accelerating delivery, qualification, and commercial launch.

o Regulatory Confidence : A unified turnkey approach ensures every system meets global cGMP, WHO, EU-GMP, USFDA, and ISO standards from the first blueprint to final validation.

• Cost Efficiency & Long-Term Reliability : Integrated design-to-delivery reduces project cost overruns and safeguards long-term operational efficiency.

==> picture [82 x 41] intentionally omitted <==

==> picture [315 x 153] intentionally omitted <==

==> picture [315 x 153] intentionally omitted <==

==> picture [315 x 153] intentionally omitted <==

3

Investor Presentation

Global Turnkey Solutions Provider to the Life Sciences & Healthcare Sectors

==> picture [82 x 41] intentionally omitted <==

==> picture [312 x 87] intentionally omitted <==

Fabtech Technologies Limited (FTL), the flagship of the Fabtech Group, brings three decades of engineering excellence to deliver start-to-finish (turnkey solutions) for pharmaceutical, biotech, and healthcare facilities worldwide. With deep capabilities across Process, Air & Water , FTL integrates design, engineering, manufacturing, and validation to build GMP-compliant, energy-efficient, and contamination-controlled environments across 62 countries .

Post-COVID, the MEA region’s focus on pharmaceutical self-reliance has accelerated FTL’s growth trajectory. Deriving 78% of revenue from MENA, GCC, and ECO Zone markets , the Company expands through FTS Cleanroom Systems LLC and strategic joint ventures. With 20 secured projects worth ₹13,724.61 lakhs , FTL continues to strengthen its position as a preferred partner for critical facility infrastructure.

Fabtech’s asset-light, integrated model combines in-house manufacturing, advanced project execution, and minimal third-party dependency to ensure speed, quality, and consistency . By mastering the pillars of Bio-Clean Air, Pure Water, and Precision Process Systems , FTL empowers nations to build resilient, sustainable, and futureready healthcare manufacturing ecosystems.

4

Investor Presentation

Key Facts & Figures

==> picture [82 x 41] intentionally omitted <==

==> picture [960 x 474] intentionally omitted <==

----- Start of picture text -----

ISO-Certified 180+ Start-To-End ₹ 90,441.87 Lakhs 135+ Projects
Operations Team Size Including Turnkey Of Order Book As Of July 31, Delivered Globally
94+ 2025
Engineering Solutions
Qualified Engineers Provider
In-House Design & Presence in 62 Countries 3 Decades of Trusted By Leading
Manufacturing Excellence with Fabtech Group’s Pharmaceutical & Biotech
Global operations in Legacy Companies
cleanrooms, HVAC, process and
automation
FY25 Financials & CAGR Growth (FY 2023-25)
₹ 33,594.21 Lakhs ₹ 4,728.87 Lakhs ₹ 4,645.29 Lakhs
Total Income EBITDA Net Profit
29.63 % CAGR 20.85 % CAGR 46.20 % CAGR
----- End of picture text -----

5

Investor Presentation

Turnkey Engineering Solutions: Driving Efficiency Across the Value Chain

==> picture [82 x 41] intentionally omitted <==

==> picture [949 x 411] intentionally omitted <==

----- Start of picture text -----

How FABTECH Fits
Design Engineering Procurement Construction Management + Project Controls
Advisory Design & Vendor New Plant/ Plant Procurement Technology Tie-up/
Consulting Conception Selection Upgradation of Equipment Transfer
Systems
Project Audit, Training, Regulatory Post Project
Management Validation Compliance Support
Experienced turnkey engineering Increased capabilities of
Capex earmarked by solution providers ensure pharmaceutical companies
pharmaceutical companies successful completion/ upgrade of through optimal utilisation of capex
capex projects
----- End of picture text -----

From Advisory to Post-Compliance Support: Start-to-End Services Covering the Entire Project Value Chain

6

Investor Presentation

Fabtech Group: A Structured Legacy of Engineering Excellence

==> picture [82 x 41] intentionally omitted <==

==> picture [177 x 118] intentionally omitted <==

----- Start of picture text -----

Group
----- End of picture text -----

==> picture [862 x 167] intentionally omitted <==

----- Start of picture text -----

FABTECH TECHNOLOGIES
TURNKEY ENGINEERING CLEANROOM PANELS
INTERNATIONAL PRIVATE
SERVICES, WATER AND AND BIO CLEAN AIR CLEANROOM EQUIPMENT
LIMITED
PROCESS EQUIPMENT EQUIPMENT
(Demerged Company)
o FT Institutions Private Limited o Fabtech Technologies Cleanrooms
o FABL International Technologies LLP Limited
----- End of picture text -----

• FT Institutions Private Limited

• o FABL International Technologies LLP o Fabtech Technologies LLC o Fabtech Lifecare LLC o FTS Cleanrooms Systems LLC o Mark Maker Engineering Private Limited o TSA Process Equipments Private Limited*

==> picture [138 x 23] intentionally omitted <==

----- Start of picture text -----

o Fabsafe Technologies
Private Limited
----- End of picture text -----

==> picture [208 x 30] intentionally omitted <==

----- Start of picture text -----

o Advantek Air Systems Private Limited
o Altair Partition Systems LLP
----- End of picture text -----

• FTS Installation Services LLP

• o Kelvin Air Conditioning and Ventilation Systems Private Limited

*Pursuant to TSA Share Purchase Agreement, Thermax Limited acquired 51% of equity share capital of our erstwhile associate company, TSA Process Equipments Private Limited (“TSA”) and finalised the terms of acquisition of the remaining 49% in a staged manner spanning over a period of two years.

7

Investor Presentation

Order Book Details

==> picture [82 x 41] intentionally omitted <==

Orders Received for the Period

(₹ in lakhs)

					(₹ in lakhs)	(₹ in lakhs)
Particulars	FY25		FY24		FY23
	Amount	%	Amount	%	Amount	%
Turnkey Projects	46,069.26 96.74% 35,409.84 87.76% 25,685.97 88.90%
Standalone Services 1,554.19 3.26% 4,940.39 12.24% 3,207.70 11.10%
Total 47,623.45 100.00% 40,350.23 100.00% 28,893.67 100.00%

Region Wise Break Up of Orders Received

(₹ in lakhs)

Particulars	FY25	FY25	FY24	FY24	FY23	FY23
	Amount	%	Amount	%	Amount	%
MENA	18,510.03 38.87% 8,905.92 22.07% 9,254.83 32.03%
ECO Zone	12,786.37 26.85% 7,235.32 17.93% 16,269.30 56.31%
GCC	8,568.95 17.99% 22,662.29 56.16% 2,582.22 8.94%
SEA	7,719.18 16.21% 0.00 0.00% 551.33 1.91%
SADAC	25.27 0.05% 1,345.61 3.33% 69.78 0.24%
EUROPE	13.67 0.03% 201.09 0.50% 165.73 0.57%
AMERICA	0.00 0.00% 0.00 0.00% 0.48 0.00%
Total	47,623.45 100.00% 40,350.23 100.00% 28,893.67 100.00%

==> picture [159 x 160] intentionally omitted <==

₹ 90,441.87 Lakhs

Total Unexecuted Order Book as on 31[st] July 2025

8

Investor Presentation

Saudi Arabia

Notable Projects Executed

The Advanced Veterinary Co

Installation and commissioning of

• Cleanrooms and related equipment

• Heat ventilation and air conditioning systems

State of

Palestine

• Purified water generation system

• Water distribution systems and other ancillary equipment.

Healthcare Pharmaceuticals Ltd

• Supply of Cleanroom Equipment

• Supply of isolator systems including Sampling isolators,

• Bangladesh Dispensing isolators, Compounding isolators.

Premier Food Industries

Installation and commissioning of

• HVAC systems

• Soft water distribution systems

• Setup of modular cleanroom partitions

Kenya

• Installation of packing machines for OSD line

• Deployment of process equipment for ointment line

==> picture [82 x 41] intentionally omitted <==

M/s. Qomel Company

The project executed for the customer included

• Supply, installation, and commissioning of equipment and utilities;

• Electro-mechanical works and water systems

• Installation, qualification, and validation of equipment.

M/s. Spectro Pharma

• Supply and commissioning of reach trucks for warehousing of Saudi disinfectants and general goods. Arabia

• Comprehensive employee training to ensure safe and optimal operations.

M/s. Laboratory & Allied Limited

The project executed for the customer included

• Construction of cleanrooms for QC Laboratory, Injectable, and OSD blocks.

Kenya

• Installation of modular partitions, HVAC, and electrical systems.

• Epoxy flooring and utility piping works.

• Water treatment plant installation with related utilities.

9

Investor Presentation

==> picture [82 x 41] intentionally omitted <==

Consolidated Result Highlights

Q2 FY26

H1 FY26

==> picture [832 x 455] intentionally omitted <==

----- Start of picture text -----

₹ 12,427.61 Lakhs ₹ 19,322.80 Lakhs
Total Total
Income Income
103.39% YoY 109.91% YoY
₹ 3,363.53 Lakhs ₹ 2,839.99 Lakhs
EBITDA EBITDA
383.76% YoY 2,678.31% YoY
27.06% 14.70%
EBITDA EBITDA
Margin Margin
1,568.59 BPS 1,358.72 BPS
₹ 2,810.61 Lakhs ₹ 2,198.02 Lakhs
Net Net
Profit Profit
449.12% YoY 101.57% YoY
22.62% 11.38%
Net Profit Net Profit
Margin Margin
1,423.91 BPS -47.03 BPS
EPS EPS
₹ 8.68 ₹ 6.79
----- End of picture text -----

==> picture [30 x 30] intentionally omitted <==

==> picture [30 x 30] intentionally omitted <==

==> picture [37 x 37] intentionally omitted <==

==> picture [36 x 37] intentionally omitted <==

==> picture [30 x 30] intentionally omitted <==

==> picture [30 x 30] intentionally omitted <==

==> picture [37 x 37] intentionally omitted <==

==> picture [37 x 37] intentionally omitted <==

==> picture [30 x 30] intentionally omitted <==

==> picture [30 x 30] intentionally omitted <==

10

*Comparative figures for Q2 FY25 & H1 FY25

Investor Presentation

Restated Consolidated Profit & Loss Statement

==> picture [82 x 41] intentionally omitted <==

In ₹ Lakhs

Particulars	FY25	FY24	FY23
Revenues from Operations	32,666.85	22,613.63	19,379.75
Other Income	927.36	446.81	611.26
Total Income	33,594.21	23,060.44	19,991.01
Cost of Material	18,185.94	12,151.43	9,164.48
Employee Benefits Expenses	3,433.65	1,978.01	1,911.39
Finance Expenses	208.63	189.98	257.55
Depreciation & Amortisation Expenses	260.78	208.11	190.26
Other Expenses	7,278.92	5,094.02	6,041.23
Total Expenditure	29,367.92	19,621.56	17,564.91
Profit before Share of profits in associate entity, exceptional items and tax	4,226.29	3,438.88	2,426.10
Share of profits in associate entity	32.22	138.14	363.77
Profit before extraordinary items and tax	4,258.51	3,577.02	2,789.87
Extraordinary Items Prior Period Item	1,784.86	0.00	0.00
PBT	6,043.37	3,577.02	2,789.87
Tax	1,398.07	855.28	616.50
Net Profit	4,645.30	2,721.74	2,173.37
Other Comprehensive Income	(12.59)	0.73	(14.93)
Total Comprehensive Income	4,632.71	2,722.47	2,158.44

11

Investor Presentation

==> picture [82 x 41] intentionally omitted <==

Restated Consolidated Balance Sheet

				In ₹ Lakhs
	Assets	FY25	FY24	FY23
	Non Current Assets
	Property, plant and equipment Goodwill	5,648.99 3,699.81	555.82 1,610.42	355.37 0.00
	Other Intangible assets	65.06	42.70	7.47
	Investments	832.22	0.10	2,024.06
	Loans	112.42	163.88	581.73
	Other financial assets	650.60	260.51	149.11
	Deferred tax asset	242.63	174.62	127.08
	Total Non Current Assets	11,251.73	2,808.05	3,244.82
	Current Assets
	Inventories	5,941.58	2,927.41	1,723.53
	Investments	642.56	2,099.99	5.06
	Trade Receivables	15,073.61	9,665.85	9,941.24
	Cash & Cash Equivalents	905.56	2,899.17	1,052.94
	Bank balances other than cash and cash equivalent	2,595.42	1,718.01	1,331.90
	Loans	242.35	165.50	98.71
	Other Financial Assets	3,549.58	2,574.62	2,006.88
	Current Tax assets	4.63	4.18	32.30
	Other current assets	1,885.43	911.12	1,949.03
	Total Current Assets	30,840.72	22,965.85	18,141.59
	Assets classified as held for sale	563.35	1,149.69	0.00
	Total Assets	42,655.80	26,923.58	21,386.41

Equities & Liabilities	FY25	FY24	FY23
Equity Share Capital	3,239.22	294.48	278.59
Reserve & Surplus	14,072.17	12,893.74	8,617.69
Non-controllingInterest	(0.03)	(0.01)	0.00
Net Worth	17,311.36	13,188.21	8,896.28
Non-Current Liabilities
Borrowings	53.44	27.68	86.47
Lease Liabilities	2,661.61	135.65	13.16
Provisions	82.02	82.64	155.37
Total Non Current Liabilities	2,797.07	245.97	255.00
Current Liabilities
Borrowings	5,408.64	960.06	3,342.24
Lease Liabilities	258.82	148.04	103.03
Trade Payables	9,880.29	6,506.11	5,399.63
Other financial liabilities	28.31	108.08	19.78
Other Current Liabilities	6,295.07	5,585.12	3,293.47
Provisions	87.35	89.53	76.98
Current tax liabilities (net)	588.89	92.46	0.00
Total Current Liabilities	22,547.37	13,489.40	12,235.13
Total Equites & Liabilities	42,655.80	26,923.58	21,386.41

12

Investor Presentation

WE ARE COMMITED TO SAVING

==> picture [122 x 60] intentionally omitted <==

Fabtech Technologies Limited

Registered Office: 715, Janki Center, Off Veera Desai Road, Andheri West, Mumbai 400 053, Maharashtra, India Phone: +91 226 159 2900

Corporate Office: 1st Floor, ABR Emerald, Plot No D8, Street 16, MIDC Andheri East, Chakala MIDC, Mumbai – 400 093, Maharashtra, India. Phone: +91 226 554 0300

Email: cs@fabtechnologies.com Website: www.fabtechnolgies.com

THANK YOU

==> picture [63 x 56] intentionally omitted <==

AKMIL Strategic Advisors Private Limited

Address: Office No. 1011, 10th Floor, Opal Square, Road No. 16, Wagle Estate, Thane (w)-400 604, Maharashtra, India Phone: +91 98209 41925

Email: info@akmiladvisors.com Website: www.akmiladvisors.com